Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients

David J. Taber, Robert E. Dupuis, Amy L. Fann, Kenneth A. Andreoni, David A. Gerber, Jeffrey Fair, Mark W. Johnson, Roshan Shrestha

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Living donor liver transplantation in adult recipients is becoming increasingly common. The liver metabolizes most drugs, including immunosuppressive agents. Right-lobe grafts used in adult living donor liver transplantation consist of only 50% to 60% of the total liver. The purpose of this study is to determine whether there is a difference between tacrolimus doses and concentrations in patients who received a partial liver transplant from a living donor (LRD) versus those who received a whole-liver transplant from a cadaveric donor (CAD). Thirteen LRD recipients and 13 CAD recipients who underwent transplantation between April 1998 and July 2000 were included in this analysis. A CAD control group matched for age, sex, and race was used for comparison. Tacrolimus doses and concentrations were analyzed weekly for the first 4 weeks, then monthly for 6 months posttransplantation. There was no difference in acute rejection rates, renal and liver function test results, or number of potentially interacting medications administered between groups. LRD recipients required significantly lower doses of tacrolimus compared with CAD recipients at 2 weeks (0.058 v 0.110 mg/kg/d; P 15 ng/mL; 22.1% v 9.2%; P <.01). In conclusion, LRD recipients have significantly decreased tacrolimus dosing requirements compared with CAD recipients during the first 3 months posttransplantation despite having similar tacrolimus concentrations.

Original languageEnglish (US)
Pages (from-to)219-223
Number of pages5
JournalLiver Transplantation
Volume8
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Living Donors
Tacrolimus
Tissue Donors
Liver
Transplants
Liver Transplantation
Liver Function Tests
Immunosuppressive Agents
Transplantation
Transplant Recipients
Kidney
Control Groups
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Taber, D. J., Dupuis, R. E., Fann, A. L., Andreoni, K. A., Gerber, D. A., Fair, J., ... Shrestha, R. (2002). Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transplantation, 8(3), 219-223. https://doi.org/10.1053/jlts.2002.30885

Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. / Taber, David J.; Dupuis, Robert E.; Fann, Amy L.; Andreoni, Kenneth A.; Gerber, David A.; Fair, Jeffrey; Johnson, Mark W.; Shrestha, Roshan.

In: Liver Transplantation, Vol. 8, No. 3, 2002, p. 219-223.

Research output: Contribution to journalArticle

Taber, DJ, Dupuis, RE, Fann, AL, Andreoni, KA, Gerber, DA, Fair, J, Johnson, MW & Shrestha, R 2002, 'Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients', Liver Transplantation, vol. 8, no. 3, pp. 219-223. https://doi.org/10.1053/jlts.2002.30885
Taber, David J. ; Dupuis, Robert E. ; Fann, Amy L. ; Andreoni, Kenneth A. ; Gerber, David A. ; Fair, Jeffrey ; Johnson, Mark W. ; Shrestha, Roshan. / Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. In: Liver Transplantation. 2002 ; Vol. 8, No. 3. pp. 219-223.
@article{2e0f381746f944e3b7c7637f02dd1d53,
title = "Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients",
abstract = "Living donor liver transplantation in adult recipients is becoming increasingly common. The liver metabolizes most drugs, including immunosuppressive agents. Right-lobe grafts used in adult living donor liver transplantation consist of only 50{\%} to 60{\%} of the total liver. The purpose of this study is to determine whether there is a difference between tacrolimus doses and concentrations in patients who received a partial liver transplant from a living donor (LRD) versus those who received a whole-liver transplant from a cadaveric donor (CAD). Thirteen LRD recipients and 13 CAD recipients who underwent transplantation between April 1998 and July 2000 were included in this analysis. A CAD control group matched for age, sex, and race was used for comparison. Tacrolimus doses and concentrations were analyzed weekly for the first 4 weeks, then monthly for 6 months posttransplantation. There was no difference in acute rejection rates, renal and liver function test results, or number of potentially interacting medications administered between groups. LRD recipients required significantly lower doses of tacrolimus compared with CAD recipients at 2 weeks (0.058 v 0.110 mg/kg/d; P 15 ng/mL; 22.1{\%} v 9.2{\%}; P <.01). In conclusion, LRD recipients have significantly decreased tacrolimus dosing requirements compared with CAD recipients during the first 3 months posttransplantation despite having similar tacrolimus concentrations.",
author = "Taber, {David J.} and Dupuis, {Robert E.} and Fann, {Amy L.} and Andreoni, {Kenneth A.} and Gerber, {David A.} and Jeffrey Fair and Johnson, {Mark W.} and Roshan Shrestha",
year = "2002",
doi = "10.1053/jlts.2002.30885",
language = "English (US)",
volume = "8",
pages = "219--223",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients

AU - Taber, David J.

AU - Dupuis, Robert E.

AU - Fann, Amy L.

AU - Andreoni, Kenneth A.

AU - Gerber, David A.

AU - Fair, Jeffrey

AU - Johnson, Mark W.

AU - Shrestha, Roshan

PY - 2002

Y1 - 2002

N2 - Living donor liver transplantation in adult recipients is becoming increasingly common. The liver metabolizes most drugs, including immunosuppressive agents. Right-lobe grafts used in adult living donor liver transplantation consist of only 50% to 60% of the total liver. The purpose of this study is to determine whether there is a difference between tacrolimus doses and concentrations in patients who received a partial liver transplant from a living donor (LRD) versus those who received a whole-liver transplant from a cadaveric donor (CAD). Thirteen LRD recipients and 13 CAD recipients who underwent transplantation between April 1998 and July 2000 were included in this analysis. A CAD control group matched for age, sex, and race was used for comparison. Tacrolimus doses and concentrations were analyzed weekly for the first 4 weeks, then monthly for 6 months posttransplantation. There was no difference in acute rejection rates, renal and liver function test results, or number of potentially interacting medications administered between groups. LRD recipients required significantly lower doses of tacrolimus compared with CAD recipients at 2 weeks (0.058 v 0.110 mg/kg/d; P 15 ng/mL; 22.1% v 9.2%; P <.01). In conclusion, LRD recipients have significantly decreased tacrolimus dosing requirements compared with CAD recipients during the first 3 months posttransplantation despite having similar tacrolimus concentrations.

AB - Living donor liver transplantation in adult recipients is becoming increasingly common. The liver metabolizes most drugs, including immunosuppressive agents. Right-lobe grafts used in adult living donor liver transplantation consist of only 50% to 60% of the total liver. The purpose of this study is to determine whether there is a difference between tacrolimus doses and concentrations in patients who received a partial liver transplant from a living donor (LRD) versus those who received a whole-liver transplant from a cadaveric donor (CAD). Thirteen LRD recipients and 13 CAD recipients who underwent transplantation between April 1998 and July 2000 were included in this analysis. A CAD control group matched for age, sex, and race was used for comparison. Tacrolimus doses and concentrations were analyzed weekly for the first 4 weeks, then monthly for 6 months posttransplantation. There was no difference in acute rejection rates, renal and liver function test results, or number of potentially interacting medications administered between groups. LRD recipients required significantly lower doses of tacrolimus compared with CAD recipients at 2 weeks (0.058 v 0.110 mg/kg/d; P 15 ng/mL; 22.1% v 9.2%; P <.01). In conclusion, LRD recipients have significantly decreased tacrolimus dosing requirements compared with CAD recipients during the first 3 months posttransplantation despite having similar tacrolimus concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0036199779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036199779&partnerID=8YFLogxK

U2 - 10.1053/jlts.2002.30885

DO - 10.1053/jlts.2002.30885

M3 - Article

VL - 8

SP - 219

EP - 223

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 3

ER -